⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMMX News
Immix Biopharma, Inc. Common Stock
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory
globenewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
accessnewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
accessnewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
accessnewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
prnewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
accessnewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
globenewswire.com
IMMX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
accessnewswire.com
IMMX